Scarica l'app Stockscreener
62.20
3.98%
2.38
Dopo l'orario di chiusura:
62.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
What downside risks could hit Cytokinetics Incorporated (KK3A) stockWeekly Trend Report & Technical Pattern Recognition Alerts - Улправда
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Goldman Sachs upgrades Cytokinetics stock rating to Buy on HCM drug potential - Investing.com
Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsTrade Volume Report & Free Community Consensus Stock Picks - Улправда
China approves Cytokinetics’ heart drug MYQORZO, triggering $7.5m payment - Investing.com Nigeria
Why Cytokinetics Incorporated stock is favored by top institutionsJuly 2025 Institutional & Capital Efficient Trading Techniques - Bollywood Helpline
On cusp of FDA and European decisions, Cytokinetics heart drug wins approval in China - The Business Journals
Cytokinetics' Hypertrophic Cardiomyopathy Treatment Approved in China - marketscreener.com
Cytokinetics rises after winning China approval for heart disease drug - TradingView — Track All Markets
Cytokinetics Wins China Approval For Myqorzo In Obstructive Hypertrophic Cardiomyopathy - Nasdaq
Cytokinetics (CYTK) Gains Approval for MYQORZO in China, Unlocks Milestone Payment - GuruFocus
Cytokinetics announces NMPA approval of Myqorzo® in China - marketscreener.com
Mirador Capital Partners LP Acquires 53,020 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Announces Nmpa Approval Of Myqorzo® In China - TradingView — Track All Markets
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy - The Manila Times
New heart drug in China approved to ease obstructive cardiomyopathy symptoms - Stock Titan
Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Insider Sell: Fady Malik Sells 2,200 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - biocentury.com
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com Canada
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Cytokinetics Receives CHMP's Positive Opinion On MYQORZO - Nasdaq
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® - GlobeNewswire
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - sharewise.com
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
0.31%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):